Form 4 Filing for Aquestive Therapeutics, Inc. - Officer Stock Acquisition

Daniel Barber, President and CEO of Aquestive Therapeutics, Inc. (AQST), acquired 293,100 Performance Stock Units (PSUs) on March 7, 2025. These PSUs are contingent rights to receive one share of common stock each, with performance measured from March 7, 2025, to March 7, 2028. Vesting occurs fully on March 7, 2028, if performance conditions are met. The pricing of the PSUs depends on the 30-day average Nasdaq closing price over specific periods. This Form 4 filing was submitted late due to an administrative oversight.